"Can Soluble-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?" (sCD163)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01463449|
Recruitment Status : Completed
First Posted : November 1, 2011
Last Update Posted : August 13, 2014
|Condition or disease||Intervention/treatment|
|Obesity Insulin Resistance Type 2-diabetes Inflammation||Procedure: gastric bypass|
Hide Detailed Description
It is recognized that low grade inflammation is a key player in the development of atherosclerosis and insulin resistance (Haslam, James 2005). Circulating levels of inflammatory markers such as high sensitive C-reactive protein (hsCRP) and interleukin (IL)-6 are found to be increased in subjects with cardiovascular disease (CVD) and type 2-diabetes (Dandona, Aljada & Bandyopadhyay 2004). We and others have shown that obesity, and in particular abdominal obesity, is associated with persistent increased level of inflammatory markers (Bruun et al. 2007, Christiansen et al. 2010a) . Thus this low grade of inflammation may represent "the common soil" for the pathogenesis of atherosclerosis and insulin resistance and represent the link between these metabolic disturbances and obesity.
Besides its function as a storage organ, the adipose tissue (AT) exerts a complex role in the organism. In obesity the adipose tissue is infiltrated by an increased amount of macrophages, and particular these macrophages express and release a wide range of hormones and cytokines, collectively called adipokines, which biological functions are shown to include involvement in glucose metabolism, lipid metabolism, adipocyte differentiation, immunity, vasculature and neuron development and eating behavior (Trayhurn, Wood 2004).
Among the adipokines expressed in the AT are pro-inflammatory cytokines as TNFα, IL-6, pro-inflammatory chemokines as IL-8, MCP-1, MIP1α, thrombotic factors as plasminogen inhibitor 1 (PAI-1), and AT specific proteins as adiponectin and leptin.
Hypertrophied adipocytes, as seen in obese subjects and associated with insulin resistance are shown to display a distinct gene expression of inflammatory markers compared to small human adipocytes and it is shown that adipocyte size is an important determinant of adipokine secretion. Moreover an positive association between the grade of obesity and the expression of pro-inflammatory cytokines as TNFα, IL-6, IL-8, has been found whereas and an inverse association between adiponectin and obesity has been reported (Kern et al. 2003, Bruun et al. 2003).In accordance with these observations, we have found the AT expression of MCP-1 was up-regulated in obese subjects (Christiansen, Richelsen & Bruun 2005) whereas the AT expression of adiponectin in obese subjects (mean BMI 40 kg/m2 ) was found down-regulated with 50% as compared to lean subjects (mean BMI 22 kg/m2) (Christiansen et al. 2010b).
Thus, adipose tissue inflammation resulting in dysfunction of the adipose tissue may be the important factor relating obesity to insulin resistance, metabolic syndrome, diabetes, and cardiovascular diseases.
CD-163 is a membrane bound receptor primary expressed in monocytes and macrophages. CD163 was originally described as a hemoglobin scavenger receptor since it is involved in removing hemoglobin released from ruptured red blood cells (Moestrup, Moller 2004). A soluble variant of CD-163 (s-CD-163) is present in plasma and is elevated in pathological condition activating the monocyte-macrophage system.
Recently s-CD-163 is associated with various inflammatory conditions (Moestrup, Moller 2004), and very recently to be a rather strong predictor of the development of type 2 diabetes in a large Danish cohort (Moller et al. 2011). Thus, s-CD-163 may be a marker both related to inflammation as well as to metabolic conditions maybe linking low grade inflammation and metabolic abnormalities, and furthermore, may be a marker of the obese state with complications.
Only a subset of overweight and obese individuals develops insulin resistance, type 2 diabetes and related diseases (Stefan et al. 2008, Bluher 2010). These "healthy" obese subjects are characterized of less adipose tissue inflammation and less insulin resistance as compared to unhealthy obese individuals. Consequently it would be of great importance to develop markers or predictors that could discriminate between "healthy" and unhealthy obese subjects in order to made a better selection for more invasive treatment such as e.g. surgery, pharmacotherapy etc.
Is CD163 pathophysiologically involved in adipose tissue inflammation in obesity? Adipose tissue (AT) is taken from various regions in lean to very obese subjects - from either subcutaneous fat biopsies (lean subjects), surgery (obese subjects - BMI> 30), and from bariatric surgery (gastric bypass) in the very obese subjects (BMI > 40) - both subcutaneous and visceral AT are investigated in parallel in the very obese individuals.
In the adipose tissue the amount of macrophages will be determined by both biochemical (e.g. CD68) and microscopically methods (immunohistochemistry). Moreover, the gene expression (PCR) and protein (Western blot) of CD163 will be detected in AT and related to the expression and protein of a number of other proinflammatory adipokines.
- Is s-CD163 a marker of adipose tissue inflammation and metabolic disturbances? Blood samples from the individuals in project 1 will also be obtained and s-CD163 measured (in house sandwich ELISA kit (Moller, Hald & Moestrup 2002)). These values will be related to the amount of macrophages in AT and the expression of CD136 in AT. Moreover, the insulin sensitivity determined by the HOMA model will be performed, and s-CD163 related to the HOMA score.
Is s-CD163 affected by weight loss, and dietary changes ( e.g. the effect of fructose (proinflammatory) and the effect of resveratrol (antiinflammatory)?
- Weight loss will be induced by bariatric surgery (bypass) in very obese subjects (BMI > 40). S-CD163 and changes in insulin sensitivity (HOMA) and other inflammatory markers (e.g. hsCRP, IL-6, TNF, MCP-1, adiponectin etc.) will be measured before and after 6 and 12 months after surgery. From power calculations it is planned to include 45 very obese subjects in this study - half of them with type 2 diabetes.
- We have performed dietary investigations with fructose (soft drinks taken for 6 months in 50 overweight and obese subjects) which induces ectopic fat accumulation in the liver determined by MR-spectroscopy and insulin resistance, and dietary intervention with resveratrol which reduces liver fat and has antiinflammatory effects. In frozen plasma samples from these studies s-CD163 will be measured in order to get insight in the dietary effect of fructose and resveratrol on this and related markers.
|Study Type :||Observational|
|Actual Enrollment :||31 participants|
|Observational Model:||Case Control|
|Official Title:||"Influence of Obesity, Weight Loss, and Diet on Low Grade Inflammation With Particular Focus on the Macrophage Marker, Soluble-CD163 - a New Predictor of Diabetes.Can s-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?"|
|Study Start Date :||November 2011|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||August 2014|
Obese subjects half with type 2-diabetes. Before and after gastric bypass. Expected reduction in weight 25 %. We expect a reduction in low grade inflammation in adipose tissue after weight loss.
Procedure: gastric bypass
Low grade inflammation in adipose tissue before and after gastric bypass
Other Name: Soluble-CD163
- Low grade inflammation in adipose tissue after weight loss induced by gastric bypass [ Time Frame: Primary endpoint after 12 months. ]sCD163 measured by enzyme-linked immunosorbent assay (ELISA). And CD163 gene expression measured by Real Time PCR (RT-PCR).
- Quantity of fat in the liver [ Time Frame: 12 months. ]The quantity of fat in the liver at baseline and again 12 months after surgery. Assessed by MR spectroscopy.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01463449
|Department of Endocrinology, Aarhus University Hospital|
|Aarhus, C, Denmark, 8000|
|Department of Endocrinology, Aarhus University Hospital|
|Aarhus, Denmark, 8000|
|Study Director:||Bjørn Richelsen, Prof. Dr.Med||Aarhus University Hospital|